Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together leading experts and young scholars in the field of urologic oncology, aiming to establish a high-level academic exchange platform and to jointly explore frontier topics and unresolved challenges in the diagnosis and treatment of urologic malignancies.
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and real-world clinical challenges, with the goal of fostering academic innovation and supporting the development of young clinicians.
Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.
Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.
Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.
Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference concluded successfully in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and clinical challenges, with the goal of fostering innovation and professional development among emerging clinicians